A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral administration of probiotic LKM512 in individuals with pre-arteriosclerosis

A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral administration of probiotic LKM512 in individuals with pre-arteriosclerosis - Effects of probiotics LKM512 in individuals with pre-arteriosclerosis: double-blind, placebo-controlled parallel group study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010813

Enrollment

Registered

2013-05-27

Start date

2013-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with high levels of serum triglyceride

Interventions

The volunteer were given an 12-week treatment with oral administration of bifidobacteria LKM512 powder (10 billion bacterial cells/package) two times per day. The volunteer were given an 12-week treat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients whose serum triglyceride level is 100 to 250 mg/dL

Exclusion criteria

Exclusion criteria: (1)Subjects who are undergoing dyslipidemia treatment (2)Subjects who take medicine that influencea value of cholesterol (3)Seriouse subjects who have complications with cardiac disease, hepatic disease, and/or renal disease (4)Subjects who was enrolled in other trails within three month. (5)Inappropriate cases evaluated by doctors

Design outcomes

Primary

Measure	Time frame
Inflammation-related markers (CoQ10, adiponectine, ICAM-a, TNF-alpha, s-LOX, LAB)	—

Countries

Japan

Contacts

Public ContactSatoshi Sakurai

Imeq CO. Ltd. CRO division

s-sakurai@imeq.co.jp03-6279-3591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026